Discussion
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…
Myeloma
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Latest news
Discussion
Discussion
Johnson & Johnson (J&J) is seeking U.S. Food and Drug Administration (FDA) approval for a quadruple treatment regimen based on Darzalex Faspro (daratumumab…
Discussion
A single infusion of the cell therapy Carvykti (ciltacabtagene autoleucel) reduced the risk of death by 45% relative to standard treatment regimens for multiple…
Discussion
The U.S. Food and Drug Administration has approved Sanofi’s Sarclisa (isatuximab) in combination with standard-of-care treatment for adults with newly diagnosed multiple myeloma…
Discussion
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) status to P-BCMA-ALLO1, Poseida Therapeutics‘ experimental CAR T-cell therapy for…
Discussion
The U.S. Food and Drug Administration (FDA) has approved Boruzu, a ready-to-use injectable formulation of bortezomib, for treating adults with multiple myeloma and mantle…
